Medicine is entering a new era — one in which the goal is no longer simply to treat disease, but to restore function, regenerate tissue, and reimagine the healthy lifespan and limits of the human body.
However, revolutionary therapies alone do not transform medicine. What truly changes healthcare is infrastructure: the systems, safety frameworks, technologies, and data intelligence that propel innovation from isolated breakthroughs into scalable clinical practice.
Few leaders understand this distinction better than Dr. Suzie Robertson, Pharm.D., founder and CEO of Matrix Biologics.
While many pioneers in regenerative medicine are focused on the therapies themselves, Dr. Robertson has taken on a far more ambitious challenge: building the operational and technological architecture that will allow regenerative medicine to mature into a trusted, scalable discipline within modern healthcare.
Through Matrix Biologics, Dr. Robertson and her executive leadership team — including Chief Medical Officer Dr. Lauren Beardsley, NMD, and Chief Technology Officer Erin Keyes, MPH, MBA — are building an integrated ecosystem that unites biological innovation, clinical safety systems, and provider enablement platforms. Central to this vision is a strategic partnership with Equitar Technologies to develop and deploy an FDA-cleared artificial intelligence platform designed to bring data-driven intelligence, safety guardrails, and scalable clinical precision to regenerative medicine. Their goal is not simply to participate in the regenerative medicine revolution; it is to establish a robust foundation that enables regenerative medicine to advance responsibly into broad, mainstream clinical adoption.
“Medical breakthroughs change what is possible — but it is infrastructure, safety, and data that determine whether those breakthroughs can truly change the world.”
— Dr. Suzie Robertson
A Career Built on Safety, Systems, and Clinical Integrity
Dr. Robertson’s perspective on regenerative medicine is shaped by more than two decades inside one of healthcare’s most disciplined environments: hospital pharmacy.
Throughout her career as a clinical pharmacist, compliance officer, medication safety leader, and clinical informaticist, Dr. Robertson has led the development of advanced systems and safety frameworks designed to prevent medical errors and safeguard patient lives.
She leads the design of clinical protocols, implements rigorous compliance frameworks, and deploys cutting-edge health information technologies that enable physicians to make safer, data-driven decisions.
Regenerative medicine inspired her to investigate how cutting-edge science could transform patient outcomes.
What she discovered was both exciting and concerning.
“Regenerative therapies have enormous potential to support the body’s natural healing processes,” Dr. Robertson explained. “But the industry lacks the infrastructure that modern healthcare depends on — standardized protocols, safety intelligence, and measurable outcomes.”
These experiences revealed a critical truth: if regenerative therapies were to reach patients responsibly, the industry needed structure, oversight, and measurable outcomes. That insight became the guiding vision behind the founding of Matrix Biologics.
Rather than simply distributing regenerative solutions, Dr. Robertson set out to build something far more ambitious: a technology-enabled provider ecosystem designed to support the widespread adoption of regenerative medicine.
When Personal Experience Meets Scientific Opportunity
For Dr. Robertson, the decision to pursue this mission was not purely professional — it was also deeply personal.
Her husband, a Marine veteran, had endured debilitating back pain for more than two decades. Despite access to top specialists, surgical consultations, and a long list of conventional treatments, his quality of life continued to deteriorate.
One day, she found him collapsed on the floor, unable to move.
“We were in our early 40s, and we were forced to ask ourselves what the next 30 years of our lives were going to look like,” she said.
After extensive research, Dr. Robertson pursued regenerative therapy using exosome-based biologics.
The results were remarkable.
Within weeks, her husband, who had been immobilized, was back in the pool playing with their four daughters. Five years later, he continues to enjoy a full recovery.
A second experience soon followed.
A close friend — now CFO of Matrix Biologics — was suffering severe respiratory complications from long-haul COVID. After months of emergency room visits and consultations with multiple specialists, his symptoms continued to worsen.
That’s when Dr. Robertson stepped in and brought him to Scottsdale for regenerative therapy.
Less than 24 hours later, he reported that his symptoms had disappeared.
“The experience made one thing crystal clear: regenerative therapies can only reach patients safely and effectively when the industry is built on rigorous structure, oversight, and measurable outcomes,” Dr. Robertson said.
That insight became the blueprint for Matrix Biologics: How can we change lives, change outcomes?
Building the Operating System for Regenerative Medicine
Matrix Biologics was founded on a single principle: Innovation without safety and infrastructure cannot transform healthcare.
To address this challenge, Matrix Biologics developed SafetyFirst Provider Solutions™, a comprehensive platform that enables healthcare providers to implement regenerative medicine programs within existing clinical workflows.
At the center of this platform is the company’s Matrix SharedSolutions™ Program for Partnered Distribution, a purpose-built framework designed to drive leading distributors and healthcare providers to expand regenerative medicine programs responsibly, while maintaining clinical oversight and operational efficiency.
Through SharedSolutions™, Matrix provides scalable systems, certified technologies, and credentialed professional support, enabling providers to expand regenerative medicine programs efficiently. The platform supports both post-market biologic therapies and investigational clinical programs, enabling integration of new regenerative protocols without major increases in staff or infrastructure.
The platform integrates:
- Product access and investigational studies
• Certified patient education and engagement tools
• Accredited physician training and continuing medical education
• Clinical program implementation within existing workflows
• Electronic data capture and longitudinal patient monitoring
• Real-world outcomes analysis and safety reporting
• AI-powered safety and statistical intelligence
In addition to supporting individual providers, the SharedSolutions™ Program enables distributors and healthcare organizations to expand regenerative medicine programs across networks of Tier One provider accounts, offering centralized dashboards, reporting tools, and full operational visibility across the patient care and follow-up lifecycle.
These capabilities are supported by Matrix’s Integrated Safety Intelligence™ technologies, which transform clinical experiences into structured, anonymized data that physicians can use to refine treatment protocols and monitor safety outcomes.
The result is a new operational model for regenerative medicine that emphasizes clinical excellence, transparency, and continuous learning while empowering providers and distribution partners to expand responsibly.
“Our goal is to empower providers to deliver regenerative therapy safely and effectively, while upholding the highest standards of oversight and patient safety,” Dr. Robertson said.
Where Biology Meets Intelligence
A defining feature of Matrix Biologics’ platform is the integration of FDA-cleared artificial intelligence technologies designed specifically for regenerative medicine.
The AI platform serves as a digital co-pilot for physicians, interpreting imaging, guiding patient evaluations, and analyzing treatment outcomes across a growing network of providers.
By aggregating real-world clinical data, the system empowers physicians to identify patterns and refine protocols in ways that were previously impossible.
Robertson describes this convergence as the intersection of biology and intelligence, ultimately changing outcomes.
“Biology restores and AI redefines,” she said. “When you combine regenerative science with advanced analytics, you create the safety guardrails and outcome visibility that modern healthcare requires.”
Leading the Next Era of Medicine
As regenerative medicine continues to expand, she cautions that the field’s rapid growth must be accompanied by greater transparency and accountability.
Her extensive background in pharmacy, compliance, clinical informatics, and patient safety makes her particularly vocal about the need for standardized dosing, validated sourcing, and measurable outcomes.
“How can we be certain of the sourcing and potency of every manufacturer?” she proposed. “If providers don’t have clear measurement and real-world data, they’re essentially practicing in the dark.”
Architecting the Future of Regenerative Healthcare
For Dr. Robertson, the transformation of regenerative medicine is not simply about new treatments. It is about building the systems that allow those treatments to reach patients safely and responsibly.
Through Matrix Biologics, she is constructing the infrastructure that will allow regenerative medicine to mature into a trusted, scalable medical discipline — poised to be fully integrated into mainstream medicine.
“The future of medicine belongs to leaders who combine science, compliance, data, and heart,” she said.
By bringing together biological innovation, artificial intelligence, and clinical safety frameworks, Matrix Biologics is reshaping how regenerative treatments are delivered, studied, and ultimately adopted across modern healthcare.
Within the healthcare ecosystem, Dr. Robertson and her team are reimagining modern medicine; regenerative medicine is no longer a fragmented frontier. It will be a structured, data-driven platform for the future of medicine.
To join the movement of changing lives and changing outcomes, visit Matrix Biologics – FDA-Approved Distribution | Built for Providers.
